Experienced in Undifferentiated Pleomorphic Sarcoma

Dr. Victor M. Priego

Hematology Oncology | Oncology
Johns Hopkins Medicine
Center For Cancer & Blood Disorders
Bethesda, MD 
Offers Telehealth

Experienced in Undifferentiated Pleomorphic Sarcoma
Johns Hopkins Medicine
Center For Cancer & Blood Disorders
Bethesda, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Victor Priego is a Hematologist Oncology specialist and an Oncologist in Bethesda, Maryland. Dr. Priego is rated as an Experienced provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Myelodysplastic Syndrome (MDS), Anemia, Hemangioma Thrombocytopenia Syndrome, Thrombocytopenia, and Splenectomy.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Residency
Providence Health & Services, Medicine, 1979
Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in MD
Board Certifications
American Board Of Internal Medicine
Fellowships
Georgetown University School of Medicine, Oncology, 1983
Georgetown University School of Medicine, Hematology, 1981
Howard University Hospital, Hematology, 1980
Hospital Affiliations
Suburban Hospital
Languages Spoken
English
Italian
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Center for Cancer & Blood Disorders
Suite 660, Bethesda, MD 20817
Call: 301-571-0019

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


6 Clinical Trials

A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Drug
Study Drug: ASTX727
Study Phase: Phase 1/Phase 2
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
Enrollment Status: Terminated
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: CG-806
Study Phase: Phase 1
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drugs: Cedazuridine, Decitabine
Study Phase: Phase 3
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: September 21, 2022
Intervention Type: Drug, Dietary supplement, Biological
Study Drugs: Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Dexamethasone
Study Phase: Phase 2
A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination With Pomalidomide, Carfilzomib and Dexamethasone Among High Risk Relapsed/ Refractory Multiple Myeloma Patients
A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination With Pomalidomide, Carfilzomib and Dexamethasone Among High Risk Relapsed/ Refractory Multiple Myeloma Patients
Enrollment Status: Terminated
Publish Date: March 31, 2022
Intervention Type: Drug
Study Drugs: Elotuzumab, Pomalidomide, Carfilzomib, Dexamethasone
Study Phase: Phase 2
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Enrollment Status: Completed
Publish Date: November 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

9 Total Publications

ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia Vera.
ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia Vera.
Journal: Acta haematologica
Published: December 16, 2024
View All 9 Publications
Similar Doctors
Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Dennis A. Priebat
Hematology Oncology | Oncology
Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Dennis A. Priebat
Hematology Oncology | Oncology
110 Irving St Nw, Suite 2a38, 
Washington, DC 
 (9.1 miles away)
202-877-2505
Languages Spoken:
English
See accepted insurances

Dennis Priebat is a Hematologist Oncology specialist and an Oncologist in Washington, Washington, D.c.. Dr. Priebat is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Mesenchymoma, and Rhabdomyosarcoma Embryonal.

Christian F. Meyer
Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Christian F. Meyer
Oncology
Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Christian F. Meyer
Oncology

Skip Viragh Outpatient Cancer Center

201 North Broadway Street, Viragh BLDG 5th FL, Viragh BLDG 5th FL, 
Baltimore, MD 
 (33.5 miles away)
410-955-8964
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. Meyer will serve as the lead medical oncologist for adult sarcoma patients, and will focus on building the Adult Sarcoma and Connective Tissue Oncology Program. In collaboration with pediatric oncologist David Loeb, M.D., Ph.D., and orthopaedic surgeon Kristy Weber, M.D., Meyer will bring novel therapies to the clinic for sarcoma patients. Meyer received his bachelors and masters degrees in cell and molecular biology from Stanford University. From there, he joined the Medical Scientist Training Program at Baylor College of Medicine and earned his medical degree followed by a doctorate in immunology. Meyer completed his residency at the University of Maryland and served as chief resident in medicine from 2004-2005. Afterward, he joined our fellowship program in medical oncology and has been working in the laboratory of Jonathan Powell, M.D., Ph.D., on projects relating to the characterization of molecular regulatory pathways involved in T-cell activation and energy. As a third-year fellow, Meyer served as the chief fellow for our Training Programs in Hematology and Medical Oncology and he received a Young Investigator Award from the American Society of Clinical Oncology in 2010. Dr. Meyer is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Mesenchymoma, Undifferentiated Pleomorphic Sarcoma, Bone Tumor, and Ganglioneuroblastoma.

Karim Boudadi
Advanced in Undifferentiated Pleomorphic Sarcoma
Dr. Karim Boudadi
Oncology | Otolaryngology | Hematology Oncology
Advanced in Undifferentiated Pleomorphic Sarcoma
Dr. Karim Boudadi
Oncology | Otolaryngology | Hematology Oncology

Sibley Memorial Hospital

5255 Loughboro Road Northwest, Building B, Building B, 
Washington, DC 
 (6.5 miles away)
202-660-6500
Languages Spoken:
English, French, Spanish
See accepted insurances
Offers Telehealth

Karim Boudadi, M.D., is a medical oncologist and hematologist with the Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital in Washington, D.C., and an assistant professor in the Department of Oncology at Johns Hopkins University School of Medicine. Listen to Dr. Boudadi’s Cancer Matters podcast episode to learn more about his work. Dr. Boudadi has expertise in treating cancers of the head and neck, including salivary gland cancers, as well as cancers of the esophagus, and bone and soft tissue sarcomas. Having completed dual training in medical oncology and hematology at Johns Hopkins University, Dr. Boudadi also treats patients with benign hematologic conditions or non-cancer related blood disorders, such as anemia, low blood counts, bleeding disorders, and clotting disorders. Dr. Boudadi earned his medical degree from the University of Rochester School of Medicine. He completed a residency in internal medicine at the University of Michigan in Ann Arbor, MI, and went on to serve as a clinical lecturer in the Department of Internal Medicine at the University of Michigan Medical School before joining Johns Hopkins. He then completed dual fellowship training in both hematology and medical oncology at the Johns Hopkins University School of Medicine. Dr. Boudadi's research during his fellowship focused on prostate cancer and immunotherapy. Dr. Boudadi is a member of the American Society of Clinical Oncology, the American Society of Hematology, the American College of Physicians, and the American Medical Association. He is also a member of the Hematology and Oncology Fellowship Selection Committee at The Johns Hopkins University School of Medicine. Dr. Boudadi has extensive clinical trial development experience and has published his work in peer-reviewed journals. His primary research interest is immunotherapy. Recent News Articles and Media Coverage Cancer Matters Podcast: Dr. Bill Nelson discussing the treatment of HPV related head and neck cancers, Johns Hopkins Kimmel Cancer Center Podcasts (May 23, 2019). Dr. Boudadi is rated as an Advanced provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Glioma, Mesenchymoma, Undifferentiated Pleomorphic Sarcoma, Gastrointestinal Stromal Tumor, and Prostatectomy.

VIEW MORE UNDIFFERENTIATED PLEOMORPHIC SARCOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Priego's expertise for a condition
ConditionClose
    • Distinguished
    • Anemia
      Dr. Priego is
      Distinguished
      . Learn about Anemia.
      See more Anemia experts
    • Myelodysplastic Syndrome (MDS)
      Dr. Priego is
      Distinguished
      . Learn about Myelodysplastic Syndrome (MDS).
      See more Myelodysplastic Syndrome (MDS) experts
    • Advanced
    • Adult Immune Thrombocytopenia
      Dr. Priego is
      Advanced
      . Learn about Adult Immune Thrombocytopenia.
      See more Adult Immune Thrombocytopenia experts
    • Cyclic Neutropenia
      Dr. Priego is
      Advanced
      . Learn about Cyclic Neutropenia.
      See more Cyclic Neutropenia experts
    • Deep Vein Thrombosis
      Dr. Priego is
      Advanced
      . Learn about Deep Vein Thrombosis.
      See more Deep Vein Thrombosis experts
    • Essential Thrombocythemia
      Dr. Priego is
      Advanced
      . Learn about Essential Thrombocythemia.
      See more Essential Thrombocythemia experts
    • Hemangioma Thrombocytopenia Syndrome
      Dr. Priego is
      Advanced
      . Learn about Hemangioma Thrombocytopenia Syndrome.
      See more Hemangioma Thrombocytopenia Syndrome experts
    • Immune Thrombocytopenic Purpura (ITP)
      Dr. Priego is
      Advanced
      . Learn about Immune Thrombocytopenic Purpura (ITP).
      See more Immune Thrombocytopenic Purpura (ITP) experts
    View All 17 Advanced Conditions
    • Experienced
    • Adult Soft Tissue Sarcoma
      Dr. Priego is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Agranulocytosis
      Dr. Priego is
      Experienced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Priego is
      Experienced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Alpha Thalassemia
      Dr. Priego is
      Experienced
      . Learn about Alpha Thalassemia.
      See more Alpha Thalassemia experts
    • Alpha Thalassemia X-Linked Intellectual Disability Syndrome
      Dr. Priego is
      Experienced
      . Learn about Alpha Thalassemia X-Linked Intellectual Disability Syndrome.
      See more Alpha Thalassemia X-Linked Intellectual Disability Syndrome experts
    • Anal Cancer
      Dr. Priego is
      Experienced
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    View All 88 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.